Selected references for the introduction of innovations

Breast cancer: Mammography United Kingdom1 The Netherlands2 Germany3 France4 Spain5 Estonia6 Sweden7

Breast cancer: Tamoxifen United Kingdom8 The Netherlands9 Germany10 France11 Spain12 Estonia13 Sweden14

Cervical cancer: Cervical screening United Kingdom15 The Netherlands15 Germany15 France16 Spain17 Estonia18 Sweden15

Testicular cancer: Cisplatin United Kingdom19 The Netherlands20 Germany21 France22 Spain23 Estonia13 Sweden24

Hodgkin’s disease: High dose therapy and peripheral blood stem cell transplantation United Kingdom25 The Netherlands26 Germany27 France28 Spain29 Estonia30 Sweden31

Leukemia: Improved treatment of disease process and complications for younger patients United Kingdom32 The Netherlands33 Germany34 France35 Spain36 Estonia: No data Sweden37

1 References

1. Roberts MM, Alexander FE, Anderson TJ, Forrest AP, Hepburn W, Huggins A, Kirkpatrick AE, Lamb J, Lutz W, Muir BB. The Edinburgh randomised trial of screening for breast cancer: description of method. Br J Cancer 1984;50(1):1-6. 2. Verbeek AL, Hendriks JH, Holland R, Mravunac M, Sturmans F, Day NE. Reduction of breast cancer mortality through mass screening with modern mammography. First results of the Nijmegen project, 1975-1981. Lancet 1984;1(8388):1222-4. 3. Perleth M, Busse R, Gibis B, Brand A. Evaluation of preventive technologies in Germany: case studies of mammography, prostate cancer screening, and fetal ultrasound. Int J Technol Assess Health Care. 2001;17(3):329-37. 4. Mamelle N, Lacour A, Anes A, Bazin B, Chaperon J, Duru G, Piette C, San Marco JL, Schaffer P, Arnold F, et al. Experience in mass screening of breast cancer with mammography in France. (In French) Rev Epidemiol Sante Publique. 1994;42(1):34-49. 5. Turabián JL, Ruiz R. Program of early detection of breast cancer in Castilla-la-Mancha. Preliminary data of the first 5 months of performance. Regional Group on the Evaluation of the Program of Early Detection of Breast Cancer. (In Spanish). Rev Sanid Hig Publica 1994;68(3):377-83. 6.http://www.haigekassa.ee/files/est_raviasutusele_ravijuhendid_andmebaas_tunnustatud/Rinnavahk.pdf. 7. Nyström L, Andersson I, Bjurstam N, Frisell J, Nordenskjöld B, Rutqvist LE. long-term effects of mammography screening: updated overview of the Swedish randomised trials. Lancet 2002;359:909- 919. 8. Ribeiro G, Swindell R. The Christie Hospital adjuvant tamoxifen trial. Natl Cancer Inst Monogr 1992;11:121- 5. 9. Beex L, Burghouts J, van Turnhout J, Breed W, Hillen H, Holdrinet A, Boetius G, Hoogendoorn G, Doesburg W, Verhulst M, et al. Oral versus im administration of high-dose medroxyprogesterone acetate in pretreated patients with advanced breast cancer. Cancer Treat Rep 1987;71(12):151-6. 10. Kaufmann M. Current trials of the German Adjuvant Breast Cancer Group (GABG). Recent Results Cancer Res 1998;152:471-8. 11. Mauriac L, Durand M, Chauvergne J, Bonichon F, Avril A, Mage P, Dilhuydy MH, Le Treut A, Wafflart J, Marée D, et al. Adjuvant trial for stage II receptor-positive breast cancer: CMF vs. CMF + tamoxifen in a single centre. Breast Cancer Res Treat. 1988;May;11(2):179-86. 12. Bellmunt J, Solé L. European early phase II dose-finding study of droloxifene in advanced breast cancer. Am J Clin Oncol. 1991;14 (Suppl 2:S):36-9. 13. State Agency of Medicine. Estonia. 14. Rutqvist LE, Cedermark B, Glas U, Johansson H, Nordenskjöld B, Skoog L, Somell A, Theve T, Friberg S, Askergren J. The Stockholm trial on adjuvant tamoxifen in early breast cancer. Correlation between estrogen receptor level and treatment effect. 15. Anttila A, Ronco G, Clifford G, Bray F, Hakama M, Arbyn M, Weiderpass E. Cervical cancer screening programmes and policies in 18 European countries. Br J Cancer 2004;91:935-41. 16. http://www.invs.sante.fr/publications/2007/cancer_col_uterus%20evaluation/col_uterus.pdf. 17. Plug I, Hoffmann R, Mackenbach J (eds). AMIEHS. Avoidable mortality in the European Union: towards better indicators for the effectiveness of health systems. Final report. Rotterdam: Department of Public Health, Erasmus MC, 2011. ( http://amiehs.lshtm.ac.uk ) 18. Raud T, Klaar U. Pilot project of cervical cancer in Estonia. (In Estonian). Eesti Arst 2006;85:834-8. 19. Medical Research Council Working Party on Testicular Tumours. Prognostic factors in advanced non- seminomatour germ-cell testicular tumours: results of a multicentre study. Report. The Lancet 1985;325:8-11. 20. Stoter G, Sleijfer DT, Vendrik CP, Schraffordt Koops H, Struyvenberg A, Van Oosterom AT, Brouwers TM, Pinedo HM. Combination chemotherapy with cis-diammine-dichloro-platinum, vinblastine, and bleomycin in advanced testicular non-seminoma. Lancet 1979;313:941-5. 21. Osieka R, Bruntsch U, Gallmeier WM, Seeber S, Schmidt CG. Cis-Diamino-dichloro-platinum (II) in the treatment of otherwise treatment-resistant malignant testicular teratoma. (In German). Dtsch Med Wochenschr 1976;101:191-5, 99. 22. Flamant F, Schwartz L, Delons E, Caillaud JM, Hartmann O, Lemerle J. Nonseminomatous malignant germ cell tumors in children. Multidrug therapy in Stages III and IV. Cancer 1984:1687-91. 23. Ministry of Health. Agencia Española del Medicamento y Productos Sanitarios (AEMPS). 24. Aass N, Klepp O, Cavallin-Stahl E, Dahl O, Wicklund H, Unsgaard B, Baldetorp L, Ahlstrom S, Fossa SD. Prognostic factors in unselected patients with nonseminomatous metastatic testicular cancer: a multicenter experience. Journal of Clinical Oncology 1991;9:818-26. 25. http://www.nice.org.uk/nicemedia/pdf/NICE_HAEMATOLOGICAL_CSG.pdf

2 26. van Agthoven M, Vellenga E, Fibbe WE, Kingma T, Uyl-de Groot CA. Cost analysis and quality of life assessment comparing patients undergoing autologous peripheral blood stem cell transplantation or autologous bone marrow transplantation for refractory or relapsed non-Hodgkin's lymphoma or Hodgkin's disease. a prospective randomised trial. Eur J Cancer 2001;37:1781-9. 27. Josting A, Rueffer U, Franklin J, Sieber M, Diehl V, Engert A. Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group. Blood. 2000 2000;96:1280-6. 28. André M, Henry-Amar M, Blaise D, Colombat P, Fleury J, Milpied N, Cahn JY, Pico JL, Bastion Y, Kuentz M, Nedellec G, Attal M, Fermé C, Gisselbrecht C. Treatment-related deaths and second cancer risk after autologous stem-cell transplantation for Hodgkin's disease. Blood 1998;92:1933-40. 29. Sureda A, Arranz R, Iriondo A, Carreras E, Lahuerta JJ, García-Conde J, Jarque I, Caballero MD, Ferrà C, López A, García-Laraña J, Cabrera R, Carrera D, Ruiz-Romero MD, León A, Rifón J, Díaz-Mediavilla J, Mataix R, Morey M, Moraleda JM, Altés A, López-Guil. Autologous stem-cell transplantation for Hodgkin's disease: results and prognostic factors in 494 patients from the Grupo Español de Linfomas/Transplante Autólogo de Médula Osea Spanish Cooperative Group J Clin Oncol 2001(19):1395-404. 30. Gratwohl A, Baldomero H, Horisberger B, Schmid C, Passweg J, Urbano-Ispizua A (for the Accreditation Committee of the European Group for Blood and Marrow Transplantation (EBMT)). Current trends in hematopoietic stem cell transplantation in Europe Blood 2002;100:2374-86. 31. Glimelius B, Enblad G, Kälkner M, Gustavsson A, Jakobsson M, Branehög I, Lenner P, Björkholm M. Treatment of Hodgkin's disease: The Swedish national care programme experiences. Leukemia and Lymphoma 1996;21:71-78. 32. Marcus RE, Catovsky D, Goldman JM, Worsley AM, Galton DA. Maintenance and consolidation therapy in AML. Lancet 1984;1(8378)(Mar 24):686-7. 33. van der Does-van den Berg A, de Koning J, Reerink H, de Vries JA, van Zanen GE. Acute lymphatic leukemia in children in the Netherlands; study ALL I, 1972-1973; Dutch Childhood Leukemia Study Group. (In Dutch) Ned Tijdschr Geneeskd 1975;119:1445-51. 34. Büchner T, Urbanitz D, Emmerich B, Fischer JT, Fülle HH, Heinecke A, Hossfeld DK, Koeppen KM, Labedzki L, Löffler H, Nowrousian MR, Pfreundschuh M, Pralle H, Rühl H, Wendt FC. Multicentre study on intensified remission induction therapy for acute myeloid leukemia. Leuk Res 1982;6:827-31. 35. French Cooperative Group on Chronic Lymphocytic Leukaemia. Effectiveness of "CHOP" regimen in advanced untreated chronic lymphocytic leukaemia. Lancet. 1986 1986;14:1346-9.317-23. 36. Montserrat E, Alcalá A, Alonso C, Besalduch J, Moraleda JM, García-Conde J, Gutierrez M, Gomis F, Garijo J, Guzmán MC, et al. A randomized trial comparing chlorambucil plus prednisone vs cyclophosphamide, melphalan, and prednisone in the treatment of chronic lymphocytic leukemia stages B and C. Nouv Rev Fr Hematol 1988;30:429-32. 37. Ringdén O, Bolme P, Lönnqvist B, Gustafsson G, Kreuger A. Allogeneic bone marrow transplantation versus chemotherapy in children with acute leukemia in Sweden. Pediatr Hematol Oncol 1989;6:137- 44.

3